BUZZ-Aralez Pharmaceuticals Inc: To buy AstraZeneca drug's U.S. rights
** Canadian specialty pharmaceutical's U.S.-listed shares up 12.9 pct at $5.71 premarket, set to open at over 1- month high
** Company to buy U.S. rights of AstraZeneca Plc's old beta-blocker heart drug, Toprol-XL
** "With this deal, (Aralez) should be profitable on an adjusted EBITDA basis in 2017 and we had not expected profitability until 2020," Guggenheim analysts write
** Aralez to pay $175 mln upfront to buy U.S. rights to Toprol-XL tablets and up to $48 mln in milestone and sales-related payments, as well as mid-teen percentage royalties on sales
** Aralez expects deal to immediately add to adjusted EBITDA
** Up to Monday's close, stock lost more than a quarter of its value YTD
© Thomson Reuters 2017 All rights reserved.